Propaganda or the cost of innovation? Challenging the high price of new drugs

BMJ (Online)

Volumn 352, Issue , 2016, Pages

  Ghinea, Narcyz ^a   Lipworth, Wendy ^a   Kerridge, Ian ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOSERINE; ERIBULIN; ESOMEPRAZOLE; GENERIC DRUG; IMATINIB; IMMUNOSUPPRESSIVE AGENT; IVACAFTOR; NAPROXEN; NITROPRUSSIDE SODIUM; PYRIMETHAMINE; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE; SOFOSBUVIR;

ARTICLE; BREAST CANCER; BUDGET; CONFIDENTIALITY; COST BENEFIT ANALYSIS; CYSTIC FIBROSIS; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; ENZYME REPLACEMENT; FABRY DISEASE; FOOD AND DRUG ADMINISTRATION; FUNDING; GLYCOGEN STORAGE DISEASE TYPE 2; HEALTH INSURANCE; HEART DISEASE; HEPATITIS C; HUMAN; JUSTICE; MARKET; MAROTEAUX LAMY SYNDROME; NEOPLASM; PAIN; PREDICTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RARE DISEASE; REIMBURSEMENT; TUBERCULOSIS; DRUG DESIGN; ECONOMICS; HEALTH CARE COST; MASS COMMUNICATION; MEDICAL LITERATURE; PROPAGANDA; PUBLIC HEALTH; STATISTICS AND NUMERICAL DATA; TRENDS;

COST-BENEFIT ANALYSIS; DIFFUSION OF INNOVATION; DRUG COSTS; DRUG DESIGN; DRUG INDUSTRY; HEALTH EXPENDITURES; HUMANS; NATIONAL HEALTH PROGRAMS; PHARMACOPOEIAS AS TOPIC; PROPAGANDA;

EID: 84960976549     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.i1284     Document Type: Article

References (41)

1. IMS Institute for Healthcare Informatics. Global outlook for medicines through 2018. IMS, 2014.
2. Johnson S, Gunderson B, Bowen K, Starner CI, Gleason PP. Specialty drugs are forecasted to be 50% of all drug expenditures in 2018. http://cdn2.content.compendiumblog. com/uploads/user/e7c690e8-6ff9-102a-ac6d-e4aebca50425/accf0d87-0d14-4aa7-bbf3-193b90c8d68c/File/1f8476cb4a60eb472893ddf381c9c3ec/prediction-that-by-2018-more-than-50-percent-of-all-drug-expenditures-will-be-specialty.pdf.
3. IMS Institute for Healthcare Informatics. Developments in cancer treatments, market dynamics, patient access and value: Global oncology trend report 2015. IMS, 2015.
4. Senior M. Sovaldi makes blockbuster history, ignites drug pricing unrest. Nat Biotechnol 2014;32:501-2. doi:10.1038/nbt0614-501..24911474.
5. GlobalGenes. Rare diseases: Facts and statistics. https://globalgenes.org/rare-diseasesfacts-statistics/.
6. European Commission. European rare diseases day: Top facts on EU action. Press release, 27 Feb 2014. http://europa.eu/rapid/press-release-MEMO-14-141-en.htm.
7. Cohen JP, Felix A. Are payers treating orphan drugs differently?J Market Access Health Policy 2014;2:23513doi:10.3402/jmahp.v2.23513..
8. Simoens S, Picavet E, Dooms M, Cassiman D, Morel T. Cost-effectiveness assessment of orphan drugs: A scientific and political conundrum. Appl Health Econ Health Policy 2013;11:1-3. doi:10.1007/s40258-012-0004-y. 23329382.
9. Cohen D, Raftery J. Paying twice: Questions over high cost of cystic fibrosis drug developed with charitable funding. BMJ 2014;348:g1445. doi:10.1136/bmj.g1445. 24523379.
10. Godman B, Malmström RE, Diogene E, et al. Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?Expert Rev Clin Pharmacol 2015;8:77-94. doi:10.1586/17512433.2015.990380. 25487078.
11. Tufts Centre for the Study of Drug Development. Cost to develop and win marketing approval for a new drug is $2.6 billion. Press release, 18 Nov 2014. http://csdd.tufts.edu/news/complete-story/pr-tufts-csdd-2014-cost-study.
12. Appleby J. The Cancer Drugs Fund: Inequitable and inefficient? King's Fund, 2014. http://www.kingsfund.org.uk/blog/2014/09/cancer-drugs-fund-inequitable-and-inefficient.
13. Tufts Centre for the Study of Drug Development. Briefing: Cost of developing a new drug. 2014. http://csdd.tufts.edu/files/uploads/Tufts-CSDD-briefing-on-RD-cost-study-Nov-18,-2014.pdf.
14. Doctors Without Borders. R&D cost estimates: MSF response to Tufts CSDD study on cost to develop a new drug. Press release, 18 Nov 2014. http://www.doctorswithoutborders. org/article/rd-cost-estimates-msf-response-tufts-csdd-study-cost-develop-new-drug.
15. Avorn J. The $2.6 billion pill-methodologic and policy considerations. N Engl J Med 2015;372:1877-9. doi:10.1056/NEJMp1500848. 25970049.
16. Kantarjian H, Rajkumar SV. Why are cancer drugs so expensive in the United States, and what are the solutions?Mayo Clin Proc 2015;90:500-4. doi:10.1016/j.mayocp.2015. 01.014. 25792242.
17. Herper M. The truly staggering cost of inventing new drugs. Forbes 2012 Feb 10. http://www.forbes.com/sites/matthewherper/2012/02/10/the-truly-staggering-cost-of-inventingnew-drugs/.
18. Spitz J, Wickham M. Pharmaceutical high profits: The value of R&D, or oligopolistic rents?Am J Econ Sociol 2012;71:1-36. doi:10.1111/j.1536-7150.2011.00820.x. 22319815.
19. World Health Organisation. Trade, foreign policy, diplomacy and health: Pharmaceutical industry. 2015. http://www.who.int/trade/glossary/story073/en/
20. Angell M. The truth about the drug companies: How they deceive us and what to do about it. Random House, 2005.
21. Investopedia. Definition of free market. http://www.investopedia.com/terms/f/freemarket. asp.
22. Bach PB. Limits on Medicare's ability to control rising spending on cancer drugs. N Engl J Med 2009;360:626-33. doi:10.1056/NEJMhpr0807774. 19176475.
23. Toumi M, Remuzat C, Vataire AL, et al. External reference pricing of medicinal products: Similation-based considerations for cross-country coordination. 2014. http://ec.europa.eu/health/healthcare/docs/erp-reimbursement-medicinal-products-en.pdf.
24. Lawson C. How are pharmaceutical patent term extensions justified? Australia's evolving scheme. J Law Med 2013;21:379-98.24597388.
25. Gatesman ML, Smith TJ. The shortage of essential chemotherapy drugs in the United States. N Engl J Med 2011;365:1653-5. doi:10.1056/NEJMp1109772. 22040130.
26. Japsen B. AMA wants to stop pharma pay-to-delay tactic on generics. Forbes 2012 Nov 13. http://www.forbes.com/sites/brucejapsen/2012/11/13/ama-wants-to-stop-pharma-payto-delay-tactic-on-generics/
27. Moir H, Gleeson D. Explainer: Evergreening and how big pharma keeps drug prices high. The Conversation 2014 Nov 6. http://theconversation.com/explainer-evergreening-andhow-big-pharma-keeps-drug-prices-high-33623.
28. Wellman-Labadie O, Zhou Y. The US Orphan Drug Act: Rare disease research stimulator or commercial opportunity?Health Policy 2010;95:216-28. doi:10.1016/j.healthpol.2009. 12.001. 20036435.
29. Gilchrist A, Eder K. Turing Daraprim price hike follows a precedent. Pharmacy Times 2015 Sept 22. http://www.pharmacytimes.com/news/turing-daraprim-price-hike-followsa-precedent.
30. Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: From the perspective of a large group of CML experts. Blood 2013;121:4439-42. doi:10.1182/blood-2013-03-490003. 23620577.
31. Lakdawalla DN, Romley JA, Sanchez Y, Maclean JR, Penrod JR, Philipson T. How cancer patients value hope and the implications for cost-effectiveness assessments of high-cost cancer therapies. Health Aff (Millwood) 2012;31:676-82. doi:10.1377/hlthaff.2011. 1300. 22492883.
32. Cancer Research UK. Cancer drugs fund. 2015. http://www.cancerresearchuk.org/aboutcancer/cancers-in-general/cancer-questions/cancer-drugs-fund.
33. Deloitte Access Economics. Access to cancer medicines in Australia: Medicines Australia Oncology Industry Taskforce. 2013. http://medicinesaustralia.com.au/files/2013/07/Accessto-oncology-medicines-1707-FINALV3.pdf.
34. Adams B. NHS England sets up new 190, hep C fund. PMLIVE 2015 Jun 12. http://www.pmlive.com/pharma-news/nhs-england-sets-up-new-190m-hep-c-fund-755898.
35. Department of Health. Other supply arrangements outside the pharmaceutical benefits scheme. 2015. http://www.health.gov.au/LSDP.
36. Howell J. Opportunity cost of the cancer drug fund. BMJ 2011;342:d622doi:10.1136/bmj. d622..
37. Cancer Drug Fund: Benign or malignant? The Economist 2015 Jan 24. http://www.economist.com/news/britain/21640343-well-meaning-gesture-causing-more-and-moretrouble-benign-or-malignant.
38. Daniels N. Accountability for reasonableness. BMJ 2000;321:1300-1. doi:10.1136/bmj. 321.7272.1300. 11090498.
39. Herper M. The world's most expensive drugs. Forbes 2010 Feb 22. http://www.forbes. com/2010/02/19/expensive-drugs-cost-business-healthcare-rare-diseases.html.
40. Pollack A. Drug prices soar, prompting calls for justification. New York Times 2015 July 23. http://www.nytimes.com/2015/07/23/business/drug-companies-pushed-from-far-andwide-to-explain-high-prices.html.
41. Bach PB. Indication-specific pricing for cancer drugs. JAMA 2014;312:1629-30. doi:10. 1001/jama.2014.13235. 25279433.